Intellia Therapeutics, Inc. (NTLA)
Nasdaq: NTLA · In Vitro & In Vivo Diagnostic Substances · Cambridge, MA · filing with the SEC since 2015
Who owns Intellia Therapeutics, Inc.
As filed with the SECHolders of 5% or more
5
ARK Investment Management LLC holds 12.3% of Common Stock, as its SCHEDULE 13G/A filed Feb 3, 2026 says.
Directors and officers
15
report now, of 38 people on the record since 2016. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
ARK Investment Management LLC
SCHEDULE 13G/A · filed Feb 3, 2026 · Common Stock · 11.1% in Nov 4, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK · 5.5% in Feb 9, 2026
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
Goldman Sachs Group Inc.
SCHEDULE 13G/A · filed Feb 12, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.1% in Nov 12, 2025
Contrarius Investment Management Ltd
SCHEDULE 13G/A · filed Feb 11, 2026 · COMMON STOCK · reported falling below 5%, from 5.5% in Nov 12, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 11.2% in Jan 30, 2026
What NTLA reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
AvenCell Therapeutics Inc
An investee · investee · invested in, named in the 10-K filed Feb 26, 2026
1 subsidiary in 1 country, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
19sales
1purchases
7sales on a scheduled plan
7people selling
$2.3Msold, in dollars
$1.4Mbought, in dollars
Open-market trades on Form 4 from Nov 3, 2025 to Nov 3, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 3, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 56 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Leonard John M. | President and CEO | 7 | $1.5M | 6 | 0 | $0 |
| Dulac Edward J III | EVP, Chief Financial Officer | 3 | $200,000 | 1 | 0 | $0 |
| Dube Michael P | VP, Chief Accounting Officer | 3 | $100,000 | 0 | 0 | $0 |
| Clark Eliana | EVP, Chief Technical Officer | 2 | $100,000 | 0 | 0 | $0 |
| Lebwohl David | EVP, Chief Medical Officer | 1 | $100,000 | 0 | 0 | $0 |
| Schultes Birgit C | EVP, Chief Scientific Officer | 1 | $100,000 | 0 | 0 | $0 |
| Basta James | EVP, General Counsel | 2 | $100,000 | 0 | 0 | $0 |
| Cohen Fred E | director | 0 | $0 | 0 | 1 | $1.4M |